Pair Name	alpha-Mangostin, Cisplatin
Disease Info	[ICD-11: 2C77]	Cervical cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	HeLa	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0030
In Vivo Model	All mice were subcutaneously inoculated in the back with 5 × 106 HeLa (cervical cancer) cells. Once the tumor reached about 150 mm3, mice were divided into the following four groups: (1) control, orally administrated 0.5% carboxymethyl-cellulose, (2) the α-M treatment, was treated orally with 12.5 mg/Kg (suspended in 0.5% carboxymethyl-cellulose), (3) the CDDP treatment, intraperitoneally injected with CDDP (3 mg/Kg), and (4) the CDDP+α-M treatment, administered at the doses and by the routes aforementioned for these compounds.
Result	This effect was accompanied by increased apoptosis and ROS production by HeLa cervical cancer cells, as well as an arrest in the cell cycle. These results suggest that α-M may be useful as a neoadjuvant agent in cervical cancer therapy.

Pair Name	alpha-Mangostin, Cisplatin
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->Microenvironment
In Vitro Model	A2780	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0134
	TOV-21G	Ovarian clear cell adenocarcinoma	Homo sapiens (Human)	CVCL_3613
	SK-OV-3	Ovarian serous cystadenocarcinoma	Homo sapiens (Human)	CVCL_0532
Result	It is important to note that the cargo carried by exosomes released from drug-treated cells may be significantly different.